Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) — Stock Price
Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) is currently trading at $1.74 USD, up 0.58% today. Over the past 52 weeks, shares have ranged between $1.25 and $3.01. This page tracks Acrivon Therapeutics, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ACRV market cap overview.
Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Acrivon Therapeutics, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Acrivon Therapeutics, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
Acrivon Therapeutics, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $1.01 Million | $536.00K | $1.09 Million | $832.00K | $13.00K |
| Gross Profit | $-1.01 Million | $-536.00K | $-1.09 Million | $-832.00K | $-13.00K |
| Research & Development | $63.99 Million | $45.49 Million | $23.95 Million | $13.72 Million | $1.87 Million |
| SG&A | $25.21 Million | $21.08 Million | $8.71 Million | $2.47 Million | $1.30 Million |
| Total Operating Expenses | $88.19 Million | $66.70 Million | $32.66 Million | $16.18 Million | $3.17 Million |
| Operating Income | $-89.20 Million | $-67.24 Million | $-32.66 Million | $-16.18 Million | $-3.17 Million |
| EBITDA | $-79.55 Million | $-59.85 Million | $-32.29 Million | $-16.15 Million | $-5.29 Million |
| EBIT | $-80.56 Million | $-60.39 Million | $-32.66 Million | $-16.18 Million | $-5.31 Million |
| Interest Expense | — | — | $1.49 Million | $59.00K | — |
| Income Before Tax | $-80.56 Million | $-60.39 Million | $-31.17 Million | $-16.24 Million | $-5.31 Million |
| Income Tax Expense | — | $1.00 | $-1.49 Million | $-199.56K | $-193.30K |
| Net Income | $-80.56 Million | $-60.39 Million | $-29.68 Million | $-16.24 Million | $-5.31 Million |
Acrivon Therapeutics, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Acrivon Therapeutics, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $196.59 Million | $138.26 Million | $181.23 Million | $106.59 Million | $2.19 Million |
| Total Current Assets | $181.63 Million | $129.69 Million | $132.09 Million | $100.41 Million | $1.72 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $139.66 Million | $91.44 Million | $98.23 Million | $0.00 | — |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | $2.09 Million | $5.79 Million | $59.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $19.80 Million | $17.07 Million | $10.75 Million | $130.40 Million | $10.60 Million |
| Total Current Liabilities | $17.21 Million | $13.30 Million | $6.52 Million | $2.91 Million | $613.00K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-36.17 Million | $-31.37 Million | $-24.56 Million | $-93.97 Million | $-1.52 Million |
| Total Stockholder Equity | $176.79 Million | $121.19 Million | $170.47 Million | $-23.81 Million | $-8.41 Million |
| Retained Earnings | $-196.98 Million | $-116.42 Million | $-56.03 Million | $-24.86 Million | $-8.62 Million |
Acrivon Therapeutics, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Acrivon Therapeutics, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-65.67 Million | $-42.64 Million | $-30.12 Million | $-13.98 Million | $-2.80 Million |
| Capital Expenditures | $2.77 Million | $1.29 Million | $2.17 Million | $238.00K | $15.00K |
| Free Cash Flow | $-68.44 Million | $-43.93 Million | $-32.28 Million | $-14.22 Million | $-2.82 Million |
| Investing Cash Flow | $-51.77 Million | $50.72 Million | $-141.68 Million | $-238.00K | $-15.00K |
| Financing Cash Flow | $121.03 Million | $-1.55 Million | $101.71 Million | $112.22 Million | $2.89 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $14.29 Million | $11.62 Million | $2.19 Million | $497.00K | $3.00K |
| Depreciation | $1.01 Million | $536.00K | $364.00K | $37.00K | $13.00K |
| Change in Cash | $3.59 Million | $6.52 Million | $-70.08 Million | $98.00 Million | $71.00K |
Acrivon Therapeutics, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Acrivon Therapeutics, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 13, 2025 | -0.47 | -1.16 | +59.48% |
| Aug 13, 2025 | -0.55 | -1.09 | +49.54% |
| May 15, 2025 | -0.51 | -1.01 | +49.51% |
| Mar 27, 2025 | -0.60 | -0.77 | +22.08% |
| Nov 13, 2024 | -0.59 | -0.74 | +20.27% |
| Aug 13, 2024 | -0.52 | -0.75 | +30.67% |
| May 14, 2024 | -0.73 | -0.84 | +13.10% |
| Mar 28, 2024 | -0.86 | -0.73 | -17.81% |